Numerous studies conhave firmed the beneficial effects of SGLT2 inhibitors in CKD such as the study Dapagliflozin in Patients with chronic kidney disease (DAPA-CKD), where dapagliflozin administered in a dose of 10 mg/day in patients with or without diabetes mellitus was associated with a 44% reduced risk of progression to end stage kidney disease or death of renal causes [4]. The gene discussed is SLC5A2; the disease is chronic kidney disease.